108587-40-2

Basic information

• Product Name: N-(BENZLOXYCARBONYL)-3-AMINO-1 2-
• Synonyms: N-(BENZLOXYCARBONYL)-3-AMINO-1 2-;N-(BENZYLOXYCARBONYL)-3-AMINO-1,2-PROPAN;N-(Benzyloxycarbonyl)-3-amino-1,2-propanediol 97%
• CAS NO: 108587-40-2
• Molecular Formula: C₁₁H₁₅NO₄
• Molecular Weight: 225.242
• Product Categories: Amino Alcohols;Organic Building Blocks;Oxygen Compounds;Amino Alcohols;Building Blocks;Chemical Synthesis;Organic Building Blocks;Oxygen Compounds
• Mol File: 108587-40-2.mol

Chemical Properties

• Melting Point: 74-78 °C(lit.)
• Boiling Point: 456.1oC at 760 mmHg
• Flash Point: 229.6oC
• Appearance: /
• Density: 1.255g/cm3
• Vapor Pressure: 4.12E-09mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: N-(BENZLOXYCARBONYL)-3-AMINO-1 2-(CAS DataBase Reference)
• NIST Chemistry Reference: N-(BENZLOXYCARBONYL)-3-AMINO-1 2-(108587-40-2)
• EPA Substance Registry System: N-(BENZLOXYCARBONYL)-3-AMINO-1 2-(108587-40-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 108587-40-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
N-(Benzloxycarbonyl)-3-amino-1,2-propanediol is used as a reagent for the protection of amino groups, which is essential in organic synthesis to prevent unwanted reactions that could occur with free amino groups.
Used in Peptide Synthesis:
In the field of peptide synthesis, N-(Benzloxycarbonyl)-3-amino-1,2-propanediol serves as a crucial building block, facilitating the stepwise assembly of peptide chains and ensuring the correct sequence of amino acids.
Used in Medicinal Chemistry:
N-(Benzloxycarbonyl)-3-amino-1,2-propanediol is utilized in the synthesis of pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents. Its protective role for amino groups is particularly valuable in the creation of complex molecular structures required for effective medicinal compounds.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, N-(Benzloxycarbonyl)-3-amino-1,2-propanediol is employed as a key intermediate in the production of various drugs, highlighting its importance in drug discovery and development processes. Its ability to protect amino groups and act as a building block makes it a valuable asset in the synthesis of a wide range of pharmaceutical products.

InChI:InChI=1/C11H15NO4/c13-7-10(14)6-12-11(15)16-8-9-4-2-1-3-5-9/h1-5,10,13-14H,6-8H2,(H,12,15)

Upstream product

• 616-30-8 3-Amino-1,2-propanediol 
• 501-53-1 benzyl chloroformate 
• 1262306-22-8 benzyloxycarbonylamino-4-chlorobenzoate 
• 107-18-6 allyl alcohol 

Downstream Products

• 15791-08-9 4,6-dichloro-2-hydroxy-1,3,5-triazine 
• 125907-47-3 C₂₃H₄₃NO₄Si₂ 
• 108587-42-4 Hexadecanoic acid 1-(benzyloxycarbonylamino-methyl)-2-trityloxy-ethyl ester 
• 108587-45-7 C₃₂H₅₇N₂O₈P 
• 108587-44-6 Hexadecanoic acid 1-(benzyloxycarbonylamino-methyl)-2-[(2-bromo-ethoxy)-hydroxy-phosphoryloxy]-ethyl ester 
• 108587-43-5 Hexadecanoic acid 2-benzyloxycarbonylamino-1-hydroxymethyl-ethyl ester 
• 182680-62-2 3-(N-benzyloxycarbonyl)amino-2-hydroxypropionaldehyde 
• 137618-54-3 1-benzyloxy-3-((benzyloxycarbonyl)amino)propan-2-ol 
• 137618-70-3 2-benzyloxy-3-((benzyloxycarbonyl)amino)propanol 
• 108587-41-3 (2-Hydroxy-3-trityloxy-propyl)-carbamic acid benzyl ester 

Relevant articles and documents

Phosphate bioisostere containing amphiphiles: A novel class of squaramide-based lipids

We describe a novel class of amphiphiles with squaramide moiety as a phosphate bioisostere. Most synthesized squaramide-based amphiphiles have the favorable physicochemical properties of lipids, such as: formation of stable liposomes or giant unilamellar vesicles in aqueous solution, high phase-transition temperature, low vesicle leakage and phospholipase resistance properties.

Automated modular synthesis of Aptamer-drug conjugates for targeted drug delivery

Aptamer-drug conjugates (ApDCs) are promising targeted drug delivery systems for reducing toxicity while increasing the efficacy of chemotherapy. However, current ApDC technologies suffer from problems caused by the complicated preparation and low control

Regioselective base-free intermolecular aminohydroxylations of hindered and functionalized alkenes

Regioselective base-free intermolecular aminohydroxylations of functionalized trisubstituted and 1,1-disubstituted alkenes employing benzoyloxycarbamate 3a and catalytic OsO4 are described. In all cases, the more substituted alcohol isomer is f

Selective monoalkylation of acyclic diols by means of dibutyltin oxide and fluoride salts

Fluoride anion was found to promote monoalkylation reaction of diols by the stannylene acetal method, and selective monoalkylation of various acyclic diols was accomplished in good yields under mild conditions by employing this new method. Functional groups such as carboxylic acid ester, carboxamide, carbamate, nitrile, alkyl chloride, and ether were not affected under the reaction conditions.

Peptidyl difluorodiol renin inhibitors

A renin inhibiting compound of the formula: wherein A is a functional group; W is (1)-C(O)-,(2)-CH(OH)-or(3)-N(R?)-wherein R? is hydrogen or loweralkyl; U is (1)-C(O)-,(2)-CH?-or(3)-N(R?)-wherein R? is hydrogen or lower alkyl, with the proviso that when W is-CH(OH)-then U is-CH?-and with the proviso that U is-C(O)-or-CH?-when W is-N(R?)-; V is (1)-CH-,(2)-C(OH)-or(3)-C(halogen)-with the proviso that v is-CH--when U is-N(R?)-; Q is-CH(R?)-or-C(=CHR1a)-wherein R? is (1) loweralkyl,(2) cycloalkylalkyl,(3) arylalkyl,(4) (heterocyclic) alkyl,(5) 1-benzyloxyethyl,(6) phenoxy,(7) thiophenoxy or(8) anilino, provided that B is-CH?-or-CH(OH)-or A is hydrogen when R? is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R? is a functional group; R? is (1) loweralkyl,(2) cycloalkylmethyl or(3) benzyl; R? is-CH(OH)-or-C(O)-; R? is-CH(OH)-or-C(O)-; and Z is (1) lower alkyl,(2) aryl,(3) arylalkyl,(4) cycloalkyl,(5) cycloalkylalkyl,(6) heterocyclic or(7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.

RENIN INHIBITING COMPOUNDS

The invention relates to renin inhibiting compounds of the formula STR1 wherein A is hydrogen; loweralkyl; arylalkyl; Or 10 wherein R 10 is hydrogen or loweralkyl; NR 11 R 12 wherein R. sub.11 and R 12 are independently selected from hydrogen and loweralkyl; or R 13--CO--B wherein B is NH, O, CH 2, HNCH 2 and R 13 is loweralkyl, alkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, aminoalkyl, N-protected aminoalkyl, hydroxylated dialkylamino, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic, carboxyalkyl, or lower alkyl carboxyalkyl esters; W is N or CH: U,V may be the following combinations H,OH; OH,H; H, H; or when taken together as O represents a carbonyl with the provisos that if U,V=H, OH, then W=CH, and if U,V=O then W=N; R 1 , R 3 and R 5 are loweralkyl or hydrophilic, lipophilic or aromatic amino acid side chains and may be the same or different; R 2, R 4, R 7, R 8 and R 9 are hydrogen or loweralkyl and may be the same or different; X is NH, O, S, SO, SO 2, or CH 2 ; and R 6 is loweralkyl cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protecting group, with the proviso that R 6 may be an N-protecting group when X is NH.

Angiotensinogen analogs

The invention relates to renin inhibiting compounds of the formula STR1 wherein A is hydrogen; loweralkyl; arylalkyl; OR10 or SR10 wherein R10 is hydrogen, loweralkyl or aminoalkyl; NR11 R12 wherein R11 and R12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; STR2 wherein B is NH, alkylamino, S, O, CH2 or CHOH and R13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH2 or NR2 with the proviso that when W is CHOH then U is CH2 ; R1 is loweralkyl, cycloaklylmethyl, benzyl, α,α-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R1 is phenoxy, thiophenoxy or anilino, B is CH2 or CHOH or A is hydrogen, R3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R5 is loweralkyl, cycloalkylmethyl or benzyl; R2 and R4 are independently selected from hydrogen and loweralkyl; R6 is CHOH or CO; R7 is CH2, CF2 or CF with the proviso that when R6 is CO, R7 is CF2 ; R8 is CH2, CHR14 wherein R14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R7 and R8 taken together can be STR3 with the proviso that when R7 is CF2, R8 is CH2 ; E is O, S, SO, SO2, NR15 wherein R15 is hydrogen or loweralkyl or NR16 CO wherein R16 is hydrogen or loweralkyl; R9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R9 taken together can be N3, with the proviso that when E is NH, R9 is an N-protecting group; and pharmaceutically acceptable salts thereof.

Renin-inhibiting functionalized peptidyl aminodiols and - triols

A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.

Renin-inhibiting peptidyl heterocycles

A renin inhibiting compound of the formula:*(formula 01)* wherein A is a substituent; W is C=O, CHOH or NR2 wherein R2 is hydrogen or loweralkyl; U is C=O, CH2 or NR2 wherein R2 is hydrogen or loweralkyl, with the proviso that when W is CHOH then U is CH2 and with the proviso that U is C=O or CH2 when W is NR2; V is CH, C(OH) or C(halogen) with the proviso that V is CH when U is NR2; R1 is loweralkyl, cycloalkylalkyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, 4-hydroxybenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (unsubstituted heterocyclic)methyl, (substituted heterocyclic)methyl, phenethyl, 1-benzyloxyethyl, phenoxy, thiophenoxy or anilino, provided that B is CH2 or CHOH or A is hydrogen when R1 is phenoxy, thiophenoxy or anilino; R3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)alkyl, carboxyalkyl, (thioalkoxy)alkyl, azidoalkyl, aminoalkyl, (alkyl)aminoalkyl, dialkylaminoalkyl,(alkoxy)(alkyl)aminoalkyl, (alkoxy)aminoalkyl, benzyl or heterocyclic ring substituted methyl; R4 is loweralkyl, cycloalkylmethyl or benzyl; R5 is OH or NH2; and Z is a substituent. Also disclosed are compositions for and a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.

NEW POTENTIAL IMMUNOENHANCING COMPOUNDS. I. SYNTHESES OF 1-AMINO-1-DEOXYPHOSPHATIDYLCHOLINE DERIVATIVES

Methods for the synthesis of five 1-amino-1-deoxyphosphatidylcholine derivatives are reported.These compounds have been synthesized in the framework of a research programme addressed to find out new immunoenhancing compounds.